Font Size




Menu Style


The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.

The AVG’s specific objectives are to promote understanding of the use of antivirals and other therapeutic strategies (antibodies, immunomodulators, drug combinations, etc) against respiratory virus infections. The group collates and provides up to date information and communicates expert commentary on the emergence of antiviral resistance as well as on preclinical and clinical development of potential novel/new therapeutics.

Principal activities and areas of interest of the AVG are listed under members’ interests.



The AVG committee co-ordinates the various activities and represent the interests of the isirv-AVG. Its composition reflects the range of interests and activities of the AVG and is geographically representative of its membership. Committee members have responsibility for organizing particular activities of the group and collating information on particular subject areas for the website or publication, and integrating contributions from the AVG membership.

Members are elected, initially for a period of three years. The procedure and rules for electing new members to the committee are consistent with those adopted for election to the isirv Council. Additional Members may be co-opted from the general AVG membership to serve on the Executive Committee to ensure a balance of geography, gender, scientific interests and skills.


Members will participate in an Annual Committee Meeting, typically held during an AVG-sponsored meeting. Members also participate in conference calls to generate ideas for AVG meetings/workshops, to advise on publications and other initiatives for scientific exchange, as well as to promote the activities of the Group, and isirv as a whole.

Committee members:

Kim Armstrong92x92

Kimberly Armstrong

Biomedical Advanced Research and Development Authority (BARDA), USA

Bin Cao92x92


 Bin Cao


Capital Medical University, Beijing, China


 Helen Y Chu


University of Washington, Seattle, WA, USA

Alicia Frey

Shikha Garg

Centers for Disease Control and Prevention, Atlanta, USA.

Elena Gubareva92x92

Elena Govorkova

St Jude Children's Research Hospital, Memphis, USA 

Larisa Gubareva

Centers for Disease Control and Prevention, Atlanta, USA

Alan Hay92x92

Alan Hay

Former Director of the WHO Collaborating Centre for Reference and Research on Influenza, London, UK

AVG Past-Chair

fred hayden Small

Frederick Hayden

University of Virginia School of Medicine, Charlottesville, USA


Michael Ison 


Division of Microbiology and Infectious Diseases (DMID/NIAID/NIH)


angie lackenby92x92

Angie Lackenby

Public Health England, London, UK

R Krug

Robert Krug

University of Texas at Austin, Austin, USA

Jenny McKimm Breschkin

Jenny McKimm-Breschkin

Melbourne, Australia

Lieve Naesens92x92

Lieve Naesens

The Rega Institute, Leuven, Belgium

Andres Pizzorno92x92

Andrés Pizzorno

International Center for Research in Infectious Diseases, Lyon, France


Nahoko Shindo

World Health Organisation, Geneva, Switzerland

N Sugaya

Norio Sugaya

Keiyu Hospital, Yokohama, Japan

Emi Takashita92x92

Emi Takashita

National Institute of Infectious Diseases, Tokyo, Japan.


 Cameron Wolfe


Duke University Medical Centre, Durham, NC, USA


Sylvie van der Werf


Institut Pasteur, Paris, France


 Hui-Ling Yen


University of HongKong, Hongkong SAR, China


top of page




isirv avg logo

avg stack